Findings
A proactive risk assessment is essential for optimizing study quality by identifying and mitigating risks to human subject protection and data integrity before and during a trial. Monitoring should be comprehensive, addressing not only likely risks identified initially but also less probable, high-impact risks and unanticipated issues that emerge. The effectiveness of a monitoring strategy depends on tailoring its timing, frequency, and methods to study-specific factors like complexity and site experience. Centralized monitoring, as part of a risk-based approach, can detect systemic issues like data omissions or protocol deviations more rapidly than traditional on-site visits alone.

Recommendations
Sponsors should formally document their risk assessment methodologies and ensure these assessments directly inform the creation and revision of monitoring plans. Monitoring plans must be detailed, outlining the study design, specific data sampling strategies, and clear protocols for escalating significant issues. When significant problems are identified, sponsors must conduct a timely root cause analysis and implement corrective and preventive actions. All monitoring activities, findings, and subsequent actions should be thoroughly documented and communicated to sponsor management, clinical site staff, and other relevant parties.

Regulatory Considerations
FDA regulations mandate sponsor oversight and proper monitoring but do not prescribe specific methods, providing the flexibility for sponsors to adopt a risk-based approach. The FDA may request a sponsor's risk assessment and monitoring plan documentation during an inspection. This guidance represents the Agency's current thinking and is nonbinding, allowing sponsors to use alternative approaches if they satisfy regulatory requirements. A key focus of monitoring should be to ensure critical trial processes, such as the maintenance of blinding, are protected to maintain overall data and trial integrity.

Findings
Digital health technologies often produce noisier data with additional sources of variation compared to traditional clinical trial settings.
There is a significant challenge in maintaining participant engagement and adherence in digital trials.
The need for pilot studies to address data flow, integration, and integrity is crucial.

Recommendations
Enhance participant engagement through hybrid approaches combining digital and traditional methods.
Conduct pilot studies to test data flow and integration before full-scale trials.
Refine data management guidelines based on experiences from digital trials like AHS.
Include diverse expertise in trial leadership, such as software engineers and biostatisticians.
Plan for comprehensive data analysis, including handling missing data.

Regulatory Considerations
Ensure data security, privacy, and integrity throughout the trial.
Develop a comprehensive plan for data analysis and management.
Consider the composition of the Data & Safety Monitoring Board to include diverse expertise.

Findings
Traditional on-site monitoring, which often involves 100% source data verification, is not the most effective way to ensure data quality and can divert resources from more critical activities. A risk-based approach allows for the early identification of potential issues, enabling proactive risk mitigation and improved trial oversight. The successful implementation of RBM requires a cultural shift within organizations, moving from a reactive to a proactive mindset. Collaboration among sponsors, CROs, and sites is essential for the effective adoption of RBM methodologies.

Recommendations
Sponsors should adopt a systematic, risk-based approach to monitoring that is tailored to the specific risks of their clinical trial. This includes conducting a thorough risk assessment during the planning phase to identify critical data and processes. The use of centralized monitoring and advanced analytics should be a core component of any RBM strategy to detect unusual patterns or trends in the data. Training for all stakeholders, including site staff and monitors, is crucial for the successful implementation of RBM.

Regulatory Considerations
Global regulatory agencies, including the FDA, EMA, and Japan's PMDA, have issued guidance that supports and encourages the use of risk-based approaches to monitoring clinical trials. Regulatory submissions should include a description of the RBM methodology used in the trial and a justification for the approach taken. The adoption of RBM is consistent with Good Clinical Practice (GCP) principles, which emphasize a focus on patient safety and data quality.

Findings
Variability in imaging acquisition, display, and interpretation methods across different clinical sites can increase endpoint measurement errors, potentially compromising a trial's ability to achieve its objectives.
Standard imaging procedures used in routine medical practice are often insufficient for clinical trials, which require greater standardization to reduce variability and ensure the interpretability of results.
In open-label trials, site-based image interpretation is vulnerable to bias because knowledge of a patient's clinical status can influence assessments.
Technical factors such as equipment upgrades, software changes, and inconsistent image quality can introduce errors and undermine the consistency of imaging data collected in multicenter trials.
Lack of consistency in image reader training and performance can lead to significant variability in endpoint measurements, reducing the precision of the treatment effect estimate.

Recommendations
Sponsors should develop and implement trial-specific imaging process standards, detailed in a document called an imaging charter, that go beyond routine medical practice.
Use a centralized image interpretation process to enhance the credibility of image assessments, ensure consistency, manage reader performance, and reduce variability.
Image readers should be blinded to treatment assignments and, in most cases, to other clinical data to prevent bias in the primary endpoint assessment.
Standardize all critical imaging procedures, including equipment settings, subject preparation, image acquisition protocols, site qualification processes, and ongoing quality control monitoring.
Establish clear procedures for image data transfer, quality assessment, locking, and archiving to maintain data integrity and ensure a verifiable audit trail.

Regulatory Considerations
Sponsors are encouraged to submit the imaging charter to the FDA for review, as compliance with the charter is an important part of verifying the trial's data integrity.
The use of investigational imaging equipment, software, or interpretation tools in a clinical trial must comply with all applicable FDA regulations, including investigational device exemption (IDE) requirements.
Imaging source data and records must be retained for a minimum of two years after a marketing application is approved or an investigation is discontinued, as specified in 21 CFR 312.
The final report submitted to the FDA for review should thoroughly document all imaging processes that took place during the trial, from acquisition and interpretation to data transfer.
The clinical protocol and consent forms must describe all imaging-related risks to subjects, such as radiation exposure, for review by institutional review boards (IRBs).

Findings:
Challenges in ensuring audit trail visibility for FDA inspections.
Risks of transcription errors when converting paper records into eCRFs.
Limited integration and standardization across electronic health record systems.
Potential security vulnerabilities in electronic signatures and data transmission.
Lack of comprehensive data quality checks in eCRF systems.

Recommendations:
Ensure the use of robust audit trails to track all changes and modifications to electronic source data.
Develop data management plans outlining roles, responsibilities, and data flow processes.
Use automated data capture methods (e.g., direct device transmission to eCRFs) to minimize errors.
Train clinical investigators and staff on maintaining accurate records and using eCRF systems.
Establish clear protocols for managing and retaining source data for FDA inspections.

Regulatory Considerations:
Compliance with FDA Part 11 regulations on electronic records and electronic signatures.
Retention of original or certified copies of source documents for FDA review.
Access control measures, such as unique logins and passwords, for eCRF systems.
Adherence to data traceability requirements, including data element identifiers.
Use of secure and interoperable systems for transmitting data to the eCRF.

Findings
Emphasizes the importance of DMCs in enhancing trial participant safety.
Highlights the need for DMC independence to prevent bias.
Discusses the historical context and evolution of DMCs in clinical trials.
Notes that not all trials require a formal DMC.

Recommendations
Sponsors should consider establishing a DMC for trials with significant safety concerns.
Ensure DMC independence from sponsors to maintain objectivity.
Limit DMC use to trials where they are most beneficial due to added complexity.
Clearly define roles and responsibilities of all parties involved in trial monitoring.
Develop procedures to assess and manage potential conflicts of interest for DMC members.

Regulatory Considerations
Compliance with FDA regulations on adverse event reporting under 21 CFR 312.32 and 812.150.
Adherence to confidentiality protocols for unblinded data as per 21 CFR 314.126(b)(5).
Use of DMC recommendations to inform protocol changes while minimizing potential bias.
Maintenance of detailed records for DMC meetings and interim analyses for regulatory audits.
Engagement with FDA on early termination of trials or significant protocol changes due to safety concerns.